{
    "nctId": "NCT06580002",
    "briefTitle": "Repurposing Riluzole for Cancer-Related Cognitive Impairment: a Pilot Trial",
    "officialTitle": "Repurposing Riluzole for Augmenting Brain-Derived Neuropathic Factor (BDNF) Levels and Cognitive Function in Breast Cancer Patients Experiencing Cancer-Related Cognitive Impairment: an Interventional Pilot Clinical Trial",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 34,
    "primaryOutcomeMeasure": "Change in circulating Brain-Derived Neurotrophic Factor (BDNF) levels over time in breast cancer survivors experiencing cognitive impairment (CRCI)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosed with breast cancer\n* Past exposure to chemotherapy, radiotherapy, and/or surgery\n* Not receiving chemotherapy, radiotherapy, and/or surgery during the study\n* \u226518 years of age\n* Perceived that cognitive function has worsened since cancer diagnosis and/or beginning of cancer treatment\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Presence of metastasis\n* Unwilling to undergo neuropsychological assessments necessary for the study\n* Breastfeeding, pregnant or are planning to get pregnant during the study period\n* Suspected hypersensitivity to riluzole\n* Patients taking these potential medications/substances due to drug-drug interactions; based on specific agents listed in drug package insert (pixantrone, current smoker, abametapir, cannabis, capmatinib, methotrexate, and levoketoconazole)\n* Hepatic impairment as indicated by: AST or ALT \u2265 3x upper limit normal (ULN)",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}